Altria Group (MO) shares closed down 1.3% at $68.12 on Friday, marking the fifth consecutive session of declines for the Marlboro maker. The slide came despite a first-quarter earnings beat, as investors focused on mounting competition in the nicotine pouch segment and ongoing volume pressure in the core cigarette business.
The stock is now trading 8.6% below its 52-week high of $74.56 reached on May 1, raising questions about the sustainability of Altria's strategy of relying on price increases, share buybacks, and its dividend to offset structural headwinds. The company's annual meeting is scheduled for May 14 at 9 a.m. Eastern, with shareholders of record as of March 25 eligible to vote and submit questions online.
Q1 Earnings Beat Amid Volume Declines
Altria reported first-quarter net revenue of $5.43 billion, up 3.2% year over year. After removing excise taxes, revenue rose 5.3% to $4.76 billion. Adjusted diluted earnings per share, excluding special items, came in at $1.32, a 7.3% increase. The company reaffirmed its 2026 adjusted EPS guidance range of $5.56 to $5.72.
CEO Billy Gifford described the quarter as a “strong start to the year,” highlighting “strong income growth” from smokeable products. However, the underlying numbers tell a more challenging story. Smokeable products revenue rose 2.9%, but domestic cigarette shipments fell 2.4%. Marlboro’s share of the U.S. cigarette market slipped 1.4 percentage points to 39.7%.
Pouch Market Rivalry Heats Up
The oral nicotine segment presented a mixed picture. Altria’s on! brand shipped 46.2 million cans in the quarter, up 17.6%, but overall oral tobacco shipments dropped 3.1%. While the U.S. nicotine pouch category now accounts for 58.1% of the oral tobacco market, on!’s share within pouches fell 4.2 percentage points to 13.4%.
Competitors are making aggressive moves. Philip Morris International (PM) reported a 23.5% decline in U.S. Zyn shipments to 155 million cans in the first quarter, citing stiffer competition and regulatory challenges. Jefferies analyst Andrei Andon-Ionita noted that British American Tobacco’s (BTI) Velo brand is likely the “beneficiary” of Zyn’s volume pressure. BAT has positioned Velo as a key growth driver, with the brand rising to No. 2 in the U.S. nicotine pouch market, trailing only Zyn. Higher nicotine levels and aggressive pricing have helped Velo gain share from both Zyn and on!.
Wall Street Divided, Cash Returns Continue
Analyst sentiment on Altria remains mixed. According to MarketBeat, 12 analysts have a consensus “Hold” rating, split among five buys, five holds, and two sells. The average price target of $69.22 sits just above Friday’s closing price.
Income-focused investors continue to benefit from Altria’s cash returns. The company paid $1.78 billion in common dividends during the first quarter and repurchased $280 million of its own stock. As of April 22, Altria had 1.67 billion shares outstanding.
Regulatory and Litigation Risks Loom
The company faces a host of external threats, including ongoing litigation, FDA enforcement actions, illicit e-vapor and oral pouch products, higher taxes, and consumer downtrading to cheaper alternatives. Altria’s outlook also assumes that NJOY ACE, its pod-based vape product, will remain off the U.S. market through 2026.
With volumes shrinking, pouch competition intensifying, and regulatory overhang persisting, Altria’s bull case rests heavily on its dividend, buybacks, and pricing power. Bears counter that these levers may not be enough to offset the secular decline in smoking and the rapid evolution of the nicotine pouch landscape. Friday’s decline leaves the stock at a critical juncture ahead of next week’s shareholder meeting.
